NCT04316169
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone Therapy
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases:
Additional Notes:
Exclusions: Patients with leptomeningeal disease; Patients with uncontrolled or symptomatic CNS metastases; Patients with prior CDK 4/6 inhibitor therapy
https://ClinicalTrials.gov/show/NCT04316169